The companies aim to jointly identify and develop pre-clinical development candidates suitable for future selection as drug candidates for clinical testing.
While the original contract was exclusively targeted at therapeutics acting on G-protein coupled receptors (GPCRs), the extension also includes targets from different target classes, including ion channels and enzymes.
Boehringer will have the ownership and global responsibility for all clinical development activities, manufacture and commercialization of the compounds identified in the collaboration.
As well as ongoing research payments, Boehringer will pay Evotec pre-clinical and clinical milestones as well as royalties on drugs discovered in the collaboration.
“We are very pleased with the progress we have achieved in our collaboration with Evotec to date. This has led us to extend and expand our relationship further,” said Professor Mikael Dolsten, head of corporation division pharma research/discovery, Boehringer Ingelheim.